摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-hydroxy-6-methoxy-4-methyl-8-nitroquinoline | 81358-81-8

中文名称
——
中文别名
——
英文名称
5-hydroxy-6-methoxy-4-methyl-8-nitroquinoline
英文别名
4-methyl-5-hydroxy-6-methoxy-8-nitroquinoline;6-methoxy-4-methyl-8-nitroquinolin-5-ol
5-hydroxy-6-methoxy-4-methyl-8-nitroquinoline化学式
CAS
81358-81-8
化学式
C11H10N2O4
mdl
——
分子量
234.211
InChiKey
JGJUFNZJBLULLJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    253-257 °C (decomp)
  • 沸点:
    456.7±45.0 °C(Predicted)
  • 密度:
    1.399±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    88.2
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8

反应信息

  • 作为反应物:
    参考文献:
    名称:
    抗疟药。16.作为候选抗疟药的8-[(4-氨基-1-甲基丁基)氨基] -6-甲氧基-4-甲基-5- [3-(三氟甲基)苯氧基]喹啉的2-取代类似物的合成。
    摘要:
    制备了一系列特殊药物8-[(4-氨基-1-甲基丁基)氨基] -6-甲氧基-4-甲基-5- [3-(三氟甲基)苯氧基]喹啉的2-取代类似物(I)并评估其抑制性和预防性抗疟活性。由于该化合物显示出高水平的血液和组织裂殖活性,因此化合物I的类似物的制备受到关注。发现一种类似物8a比母体化合物I具有更高的活性和更低的毒性。此外,制备了实施例8a的三种类似物。尽管三个类似物中的两个显示出显着的抗疟活性,但两者均不如化合物8a。
    DOI:
    10.1021/jm00128a010
  • 作为产物:
    描述:
    邻苯二甲醚盐酸磷酸硫酸硝酸铁粉溶剂黄146 作用下, 以 乙醇 为溶剂, 反应 7.0h, 生成 5-hydroxy-6-methoxy-4-methyl-8-nitroquinoline
    参考文献:
    名称:
    探索未开发的化学空间:合理鉴定具有抗疟特性的新型他非诺喹类似物
    摘要:
    专利倾向于定义由马库什结构的组合性质描述的巨大化学空间。然而,新主要活性成分的优化通常是由简单的 Free Wilson 方法驱动的。这一过程导致对命中化合物附近的化学空间进行高度集中的研究,留下许多可能存在高度生物活性储层的未探索区域。这项研究旨在证明,这种公开的化学空间可以隐藏具有值得研究的有趣潜在生物活性的化合物。这强调了拓宽传统策略之外的方法的价值和必要性。因此,我们主张采用一种在早期药物发现阶段可能更有效的替代方法。我们选择2018年FDA批准的单剂量根治疟疾药物他非诺喹的案例来说明这一过程。通过对他非诺喹化学空间的深入探索,合理鉴定并合成了七种具有潜在抗疟活性的化合物。这一小组代表了迄今为止报道的 58 种类似物尚未探索的化学多样性。经过生物学评估,结果证明我们的合理设计方法已被证明是一种非常有效的探索性方法,适合早期药物发现阶段。
    DOI:
    10.1016/j.bioorg.2024.107472
点击查看最新优质反应信息

文献信息

  • Modifications of primaquine as antimalarials. 4. 5-Alkoxy derivatives of primaquine
    作者:Eugene H. Chen、Keiichi Tanabe、Andrew J. Saggiomo、Edward A. Nodiff
    DOI:10.1021/jm00390a012
    日期:1987.7
    blood schizonticides (Plasmodium berghei, mouse) and tissue schizonticides (Plasmodium cynomolgi, monkey). Several of these compounds were extremely active in both screens. Such a broad spectrum of antimalarial efficacy offers the possibility of a single drug that could cure the various relapsing and nonrelapsing malarias.
    已经合成了三十二个5-烷氧基伯氨喹,并被评估为血型裂殖剂(伯氏疟原虫,小鼠)和组织型裂殖剂(食蟹毛疟原虫,猴子)。这些化合物中的几种在两种筛选中均具有极高的活性。如此广泛的抗疟疾功效提供了一种可以治愈各种复发性和非复发性疟疾的药物。
  • 5-(Straight chain 3-12 carbon alkoxy)-8-quinolinamines and their use for
    申请人:The United States of America as represented by the Secretary of the Army
    公开号:US04554279A1
    公开(公告)日:1985-11-19
    Improved means for the chemotherapy of malaria have been achieved with 5-oxy-primaquine analogues having the formula: ##STR1## wherein R.sub.4 represents hydrogen or a methyl grouping, and R represents an alkyl group containing 3 to 12 carbon atoms and pharmaceutically acceptable salts thereof, wherein the salt-forming acid may be organic or inorganic in nature. These primaquine-related compounds afford improvement in the chemotherapy of malaria by exerting plasmodicidal action on malaria parasites which may be present in either the blood, formed tissues, or blood and formed tissues of the mammalian host. Such broad and practical spectrum of effectiveness distinguishes the said primaquine analogues, which may be administered parenterally or perorally to infected animals.
    已实现改进的疟疾化疗手段,采用具有以下结构式的5-氧基伯喹类似物:##STR1## 其中R.sub.4代表氢或甲基基团,R代表含有3至12个碳原子的烷基基团及其药用可接受盐,其中盐形成酸可以是有机的或无机的。这些伯喹相关化合物通过对可能存在于哺乳动物宿主的血液、组织或血液和组织中的疟原虫产生疟疾杀灭作用,从而改善了疟疾的化疗效果。这种广泛而实用的有效性范围区分了所述的伯喹类似物,可以通过注射或口服的方式给感染的动物使用。
  • 4-Methyl-5-(unsubstituted and substituted
    申请人:The United States of America as represented by the Secretary of the Army
    公开号:US04431807A1
    公开(公告)日:1984-02-14
    Compounds of the class including 4-methyl-5-(unsubstituted and substituted henoxy)-6-methoxy-8-(aminoalkylamino)quinolines as the free bases and pharmaceutically acceptable acid amine salts are described. The compounds are highly effective antimalarial agents which possess, surprisingly, both tissue schizonticidal (radical curative) and blood schizonticidal (suppressive) activity. In addition, these drugs have significantly better therapeutics indices than primaquine which is the current tissue schizonticidal drug of choice. Primaquine possesses no useful blood schizonticidal activity at tolerated dose levels.
    该类化合物包括4-甲基-5-(未取代和取代henoxy)-6-甲氧基-8-(基烷基基)喹啉作为自由碱和药学上可接受的酸胺盐。这些化合物是高效的抗疟疾药物,令人惊讶的是,它们具有组织红细胞分裂体杀灭(根治性)和血液红细胞分裂体杀灭(抑制性)活性。此外,这些药物的治疗指数显著优于普利昂奎,后者是目前组织红细胞分裂体杀灭药物的首选药物。普利昂奎在可耐受的剂量平下没有有用的血液红细胞分裂体杀灭活性。
  • 4-methyl-5-(unsubstituted and substituted
    申请人:The United States of America as represented by the Secretary of the Army
    公开号:US04617394A1
    公开(公告)日:1986-10-14
    Compounds of the class including 4-methyl-5-(unsubstituted and substituted phenoxy)-2,6-dimethoxy-8-(aminoalkylamino)quinolines as the free bases and pharmaceutically acceptable acid amine salts are described. The compounds are highly effective antimalarial agents which possess both tissue schizonticidal (radical curative) and blood schizonticidal (suppressive) acitivity. In addition, these drugs have significantly better therapeutic indices than primaquine which is the current tissue schizonticidal drug of choice. Primaquine possesses no useful blood schizonticidal activity at tolerated dose levels. The new 2-methoxy substituted compounds produce markedly less methemoglobin at effective dose levels and thus permit a higher degree of safety than analogs which are unsubstituted in the 2-position.
    本类化合物包括4-甲基-5-(未取代和取代的苯氧基)-2,6-二甲氧基-8-(基烷基基)喹啉作为自由碱和药学上可接受的酸胺盐。这些化合物是高效的抗疟疾药物,具有组织无性繁殖体杀灭(根治)和血液无性繁殖体杀灭(抑制)活性。此外,这些药物的治疗指数显著优于目前选择的组织无性繁殖体杀灭药物-盐酸伯氨喹。在可耐受的剂量平下,盐酸伯氨喹没有有用的血液无性繁殖体杀灭活性。新的2-甲氧基取代化合物在有效剂量平下产生的甲血红蛋白明显较少,因此比2-位未取代的类似物具有更高的安全性。
  • 5-(phenylalkoxy)primaquine compounds and their use for treatment of
    申请人:Calspan Corporation
    公开号:US04980360A1
    公开(公告)日:1990-12-25
    Improvement in the treatment of malaria has been demonstrated with 5-arylalkoxy primaquine compounds of the formula ##STR1## wherein R.sub.2 represents H or methyl, R represents an alkylene group having from about 2 to about 12 carbon atoms, R' represents a substituted or non-substituted aryl moiety, such as phenyl and napthyl, and pharmaceutically acceptable salts thereof, wherein the salt forming acid may be organic or inorganic in nature. These primaquine related compounds are effective in malarial chemotherapy, by exerting plasmodicidal activity on malarial parasites present in both the blood and formed tissues of the mammalian host. The 5-arylalkoxy primaquine compounds of the invention are at least as effective in malarial treatment as the prior art 5-alkoxy primaquine compounds, but are not as toxic as the 5-alkoxy compounds at higher dosage ranges.
    5-芳基烷氧基质甲醇类化合物的治疗疟疾的改进已经得到证明,该化合物的化学式为##STR1##其中R.sub.2代表H或甲基,R代表具有约2至约12个碳原子的烷基基团,R'代表取代或未取代的芳基基团,例如苯基和基,以及其药学上可接受的盐,其中盐形成酸可以是有机的或无机的。这些与质甲醇相关的化合物通过对哺乳动物宿主的血液和形成组织中存在的疟原虫发挥杀虫活性,在疟疾化疗中有效。本发明的5-芳基烷氧基质甲醇化合物至少与先前的5-烷氧基质甲醇化合物一样有效,但在更高剂量范围内不像5-烷氧基化合物那样有毒。
查看更多